Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome

Zhang C, Sarkar A, Wong E, Vaseghi M, Wang JJ. Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome.[...]

Investments in Childhood Community Resources and Subsequent Adult Health Outcomes

La Charite J, Dudovitz R, Choi K, Chen K, Jackson NJ, Nuckols T, Sastry N, Schickedanz A, Wong MD, Zimmerman FJ. Investments in Childhood Community[...]

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis

Repetti GG, Abel ED, Tontonoz P, Sallam T. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circ Res.[...]